ArticleAnalytical and bioanalytical chemistry2025
UHPLC-QTOF-MS-based metabolomics joint high-throughput RNA sequencing transcriptomics approach for the analysis of fecal and liver biological samples and application in a case study for the mechanism of Qing-Kai-Ling oral liquid in treating MASLD.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A tunable analytical platform for bile acid isomers: from molecular recognition to pharmaceutical quality control.Analytical and bioanalytical chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Qing-Kai-Ling (QKL) oral liquid has been increasingly used in metabolic dysfunction-associated steatotic liver disease (MASLD). However, the specific metabolic differentials and metabolic pathway mechanisms that affect the MASLD regulated by QKL remained unclear. In this study, serum biochemical analyses and hematoxylin-eosin staining of the liver revealed QKL reduced liver injury and enhanced lipid metabolism ability, respectively. To clarify the therapeutic mechanism of the QKL in the treatment of MASLD, UHPLC-QTOF-MS non-target metabolomics and RNA-Seq high-throughput sequencing analysis were used to explore the mechanism of the QKL in the treatment of MASLD from the perspective of metabolic-gene interactions. UHPLC-QTOF-MS-based untargeted metabolomics further revealed that there were 196 common differentially expressed metabolites identified among 3 groups; QKL significantly up-regulated 44 metabolites, while 11 metabolites (including N-phenylacetylglutamic acid and glycocholic acid) were downregulated significantly. Moreover, the main metabolic pathways regulated by QKL included amino acids, peptides, bile acids, carbohydrates, linoleic acids, etc. Additionally, the result of the RNA sequencing-based transcriptomics showed that a total of 984 differential genes (DEGs) were identified and 9 important DEGs were obtained. The result of the Kyoto Encyclopedia of Genes and Genomes (KEGG) demonstrated that the 984 DEGs were linked to bile acid metabolism, glycerophospholipid metabolism, insulin resistance, AMPK signaling pathway, etc. Overall, this work was the first to show that QKL regulated metabolites and genes to alleviate MASLD by the UHPLC-QTOF-MS-based untargeted metabolomics joint high-throughput RNA sequencing-based transcriptomics analysis, providing the basis and research method for the treatment of metabolic diseases by QKL and other drugs.
Indexed as
Identifiers
40310493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.